Navigation Links
Results of the RIFLE STEACS clinical trial reported at TCT 2011
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 Results of a randomized clinical trial suggest that using the transradial approach for angioplasty in patients with ST elevation acute coronary syndrome is preferable to the femoral approach, and should be the recommended access route.

Results of the Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome (RIFLE STEACS) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Bleeding complications in patients with acute coronary syndrome (ACS) are a significant predictor of mortality and recent data suggest that in these patients, the radial approach could be associated with improved mortality and morbidity.

Researchers in this trial sought to determine whether transradial access for ST elevation Acute Coronary Syndrome (STEACS) treatment is associated with better outcomes when compared to transfemoral approach

The study was a prospective, randomized, parallel group, multi-center trial. Before arterial stick for percutaneous access, all STEACS patients eligible for acute revascularization were randomized (1:1 ratio) to radial or femoral access. 1,001 STEMI patients were enrolled between January 2009 and July 2011 in four high-volume clinical sites in Italy.

The primary endpoint of the study was the rate at 30 days of net adverse clinical events (NACE), a composite of cardiac death, myocardial infarction, stroke, target lesion revascularization or non-coronary artery bypass graft (non-CABG)-related major bleeding. Secondary endpoints were individual components of NACE.

At 30 days, the rate of NACE was significantly lower in the radial group when compared to the femoral group, 13.6% vs. 21.0% respectively. This difference was determined by a reduction of both the major adverse cardiac and cerebrovascular events (MACCE), 7.2% vs. 11.4%, and of bleeding, 7.8% vs. 12.2%. In particular, the rate of cardiac death at 30 days was 9.2% in the femoral group and 5.2% in the radial group.

"Radial access in patients with ST elevation acute coronary syndrome is associated with significant clinical benefits, in terms of both lower morbidity and mortality," said Enrico Romagnoli, MD, PhD, a member of the Interventional Cardiology Unit at Policlinico Casilino in Rome, Italy.

"The radial approach should no longer just be considered a valid alternative to the femoral one, but become the recommended access site for ST elevation acute coronary syndrome," concluded Dr. Romagnoli.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
2. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
3. Combination epigenetic therapy clinical trial results
4. Results of the PARIS registry Reported at TCT 2011
5. Results of the TRIGGER-PCI trial reported at TCT 2011
6. Results of rapid gene trial reported at TCT 2011
7. Results of the BRIDGE trial reported at TCT 2011
8. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
9. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
10. E-counselling shows dramatic results in lowering blood pressure
11. Less Frequent Mammograms May Lower False-Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: